Cue Biopharma (CUE) EBT (2017 - 2026)

Cue Biopharma has disclosed EBT across 10 years of filings, most recently posting -$87.5 million for Q2 2026.

• In Q2 2026, EBT fell 937.55% year-over-year to -$87.5 million; the TTM figure through Jun 2026 stood at -$101.2 million (down 163.7% YoY), while the FY2025 annual figure was -$25.7 million, up 35.44% from the prior year.
• EBT came in at -$87.5 million for Q2 2026 at Cue Biopharma, down from $2.1 million in the prior quarter.
• In the past five years, EBT ranged from a high of $2.1 million in Q4 2025 to a low of -$87.5 million in Q2 2026.
• Average EBT over 5 years is -$15.0 million, with a median of -$12.1 million recorded in 2024.
• Year-over-year, EBT surged 122.86% in 2025 and sank 937.55% in 2026.
• Over 5 years, EBT stood at -$14.2 million in 2022, then grew by 9.18% to -$12.9 million in 2023, then climbed by 27.72% to -$9.3 million in 2024, then surged by 122.86% to $2.1 million in 2025, then plunged by 4198.22% to -$87.5 million in 2026.
• Per Business Quant data, the three most recent EBT figures were -$87.5 million in Q2 2026, $2.1 million in Q4 2025, and -$7.4 million in Q3 2025.